Latest Headlines

  1. Chai Discovery Announces Collaboration With Bristol Myers Squibb To Advance AI-Driven Antibody Discovery 8/20/2026

    Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with Bristol Myers Squibb to advance the discovery of therapeutic antibodies using artificial intelligence.

  2. SandboxAQ Launches AQPotency, Bringing Ultrafast Virtual Screening To Drug Discovery Without A Solved Protein Structure 8/19/2026

    SandboxAQ today announced the general availability of AQPotency, its Large Quantitative Model (LQM) for predicting how well a potential drug will work, now available on Claude via Model Context Protocol (MCP).

  3. DeepCyte Launches World's First Single-Cell Mechanistic Toxicity Atlas As Enterprise Pharma Pilots Advance 8/19/2026

    DeepCyte Inc., a techbio company building AI toxicology tools for drug development, today announced the launch of DeeTox Atlas™, the world's first single-cell metabolomic reference atlas of drug toxicity mechanisms.

  4. Verlytix Launches As A Related Company To LyoGenesis Manufacturing 8/19/2026

    Verlytix, a global contract testing laboratory serving the pharmaceutical and biotechnology industries, today announced the launch of its expanded quality analytical testing platform.

  5. Alzamend Neuro's Phase 1/2A Lithium Imaging Data Accepted For Oral Presentation At ISMRM Workshop On X-Nuclei MR In Barcelona, Spain 8/18/2026

    Alzamend Neuro, Inc. (Nasdaq: ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder type 1 ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), today announced that an abstract reporting pharmacokinetic imaging data for AL001, Alzamend's novel organic lithium salt, has been accepted for oral presentation at the International Society for Magnetic Resonance in Medicine ("ISMRM") Workshop on Beyond Protons: Challenges and Advances in X-Nuclei MR, to be held from September 28 – October 1, 2026 at the Universitat Oberta de Catalunya (UOC) in Barcelona, Spain.

  6. Harbour BioMed Announces NMPA Approval Of IND Application For HBM7004 For The Treatment Of Advanced Solid Tumors 8/18/2026

    Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today announced that the National Medical Products Administration (NMPA) of China has approved the Investigational New Drug (IND) application for HBM7004 for the treatment of advanced solid tumors.

  7. GenBio AI Builds First World Model Of The Human Cell 8/18/2026

    GenBio AI ('GenBio') is an AI for Science company co-founded by Nobel Laureate David Baker, leading AI scientist Eric Xing, and other prominent life science and artificial intelligence researchers from Stanford, Carnegie Mellon University, Mohamed Bin Zayed University of Artificial Intelligence, Harvard, Weizmann Institute, and other research institutions.

  8. Amygdala Neurosciences Announces FDA Clearance Of Investigational New Drug (IND) Application For ANS-858 8/18/2026

    Amygdala Neurosciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application for ANS-858, enabling the Company to advance ANS-858 into clinical development.

  9. Tagomics Introduces LiquiPath, A First-In-Class cfDNA-Based Blood Test For Multi-Organ Drug Safety Monitoring 8/17/2026

    Tagomics Ltd., a pioneering precision medicine company, today announced the launch of LiquiPathTM, a cross-species, multi-organ “liquid pathology” platform, for non-invasive drug safety monitoring.

  10. OncoC4 Announces First Patient Dosing In Phase 1 Clinical Trial Of ONC-783 For The Treatment Of Advanced Solid Tumors 8/17/2026

    OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer and neurodegenerative diseases, today announced dosing of the first patient following the clearance of the Investigational New Drug (IND) application for a Phase 1 clinical trial (NCT07408258) of ONC-783, the company's investigational T-cell engager developed based on the proprietary neoCD24 platform.